Loading...
01/11 16:21
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerning factors: declining gross margins, increased operating expenses, and widening losses. While there are strategic plans for revenue growth and cost management, the lack of clear guidance on returning to positive adjusted EBITDA and the impact of debt raise concerns. The Q&A session highlights uncertainties, particularly in the international market and the China partnership. These negatives outweigh the positives, leading to a negative sentiment prediction for the stock price over the next two weeks.
Revenue $10.1 million, a 10% increase year-over-year, driven by a higher number of revenue units but offset by a lower average selling price (ASP).
Revenue Units 186 MyoPro units delivered, up 16% year-over-year, with 57% of those units from authorizations and orders received in the third quarter.
Average Selling Price (ASP) Approximately $54,300, a 5% decrease year-over-year due to an accounting change in the prior year. Normalized for the accounting change, ASP increased 3% year-over-year.
Medicare Advantage Revenue 18% of third quarter revenue, down 18% year-over-year, constrained by high preauthorization denials and appeals processes.
International Revenue $1.8 million, up 63% year-over-year, primarily from Germany, representing 18% of total revenue.
O&P Channel Revenue $900,000, up 154% year-over-year, representing 9% of total revenue.
Pipeline 1,669 patients, an increase of 32% year-over-year. 826 patients added in Q3, up 28% year-over-year.
Backlog 208 patients, down 34% year-over-year, due to reduced Medicare Advantage authorizations and faster conversion of backlog into revenue.
Gross Margin 63.8%, down from 75.4% year-over-year, impacted by higher payroll, lease expenses, and material costs.
Operating Expenses $10 million, up 26% year-over-year, driven by higher payroll, advertising spending, and R&D efforts.
Operating Loss $3.5 million, compared to $1 million in the prior year quarter.
Net Loss $3.7 million or $0.09 per share, compared to $1 million or $0.03 per share in the prior year quarter.
Adjusted EBITDA Negative $2.7 million, compared to negative $0.6 million in the prior year quarter.
Cash, Cash Equivalents, and Short-term Investments $12.6 million as of September 30, 2025.
MyoPro 2X model: Introduced in spring, gaining traction with occupational therapists and physicians, leading to increased patient referrals.
Mobile app for MyConfig software: Development efforts ongoing, part of R&D investments.
MyoPro 3: Under development as part of R&D efforts.
International revenue: Record $1.8 million in Q3, up 63% year-over-year, driven by Germany.
O&P channel revenue: Quarterly record of $900,000, up 154% year-over-year.
Medicare Advantage coverage: Sequential increase in authorizations and orders; signed additional contract covering 35 million lives.
Pipeline growth: Patient pipeline increased 32% year-over-year to 1,669 patients.
Cost per pipeline add: Decreased due to shift in advertising from social media to TV.
Gross margin: 63.8% in Q3, down from 75.4% in prior year due to higher costs and operational changes.
MyoConnect program: Launched to engage therapists and physicians for patient referrals, reducing reliance on paid advertising.
O&P channel expansion: Focus on clinical and reimbursement education to grow adoption.
Insurance coverage expansion: Efforts to increase Medicare Advantage and private payer authorizations.
Medicare Advantage Revenue Constraints: Revenue from Medicare Advantage plans was down 18% compared to the prior year due to a high number of preauthorization denials, forcing patients into an appeals process. This creates delays and additional costs, with only 45%-50% of appeals being overturned.
Gross Margin Decline: Gross margin decreased to 63.8% from 75.4% in the prior year, impacted by higher payroll, lease expenses, material costs, and unfavorable changes in inventory overhead absorption. This represents a challenge to profitability.
Operating Loss Increase: Operating loss for Q3 2025 was $3.5 million, compared to $1 million in the prior year. This was driven by higher payroll, advertising spending, and R&D expenses, indicating financial strain.
Cost of Customer Acquisition: While efforts are being made to reduce customer acquisition costs, the company still relies heavily on advertising-driven revenues, which are costly and less sustainable compared to other channels.
Dependence on Medicare and Insurance Authorizations: A significant portion of revenue depends on Medicare and insurance authorizations, which are subject to delays and denials, impacting cash flow and revenue predictability.
International Revenue and O&P Channel Risks: While international revenue and the O&P channel are growing, they are still emerging and may not yet provide stable or predictable revenue streams.
Economic and Regulatory Risks: Changes in Medicare Advantage coverage and potential regulatory shifts could impact patient access and revenue. For example, insurance companies withdrawing from certain areas may create uncertainty in patient enrollment and coverage.
Revenue Guidance for 2025: The company reiterated its full-year 2025 revenue guidance of $40 million to $42 million, representing an increase of more than 23% over the previous year.
Revenue Diversification in 2026: The company plans to diversify revenue streams in 2026 by relying less on advertising-driven revenues and generating growth through the MyoConnect platform, further penetration of the O&P channel, and international markets.
Operating Leverage and Cash Burn in 2026: The company aims to improve operating leverage and lower cash burn in 2026.
MyoConnect Program Expansion: The MyoConnect program is expected to develop into a scalable and cost-efficient source of high-quality referrals over time, contributing to future growth.
O&P Channel Growth: The O&P channel is emerging as a high-quality, lower-cost source of qualified patients, and the company intends to continue developing this channel to diversify revenue sources.
International Market Growth: The company experienced strong growth in international markets, particularly in Germany, and anticipates continued growth in this segment.
Insurance Coverage Expansion: The company is working to expand insurance coverage, including obtaining more MyoPro authorizations from Medicare Advantage payers and signing additional contracts with private payers.
Manufacturing and Cost Improvements: The company implemented manufacturing changes to improve gross margin and managed headcount and other cost reductions to lower operating expenses, positioning for improved operating leverage as revenues grow.
The selected topic was not discussed during the call.
The earnings call reveals several concerning factors: declining gross margins, increased operating expenses, and widening losses. While there are strategic plans for revenue growth and cost management, the lack of clear guidance on returning to positive adjusted EBITDA and the impact of debt raise concerns. The Q&A session highlights uncertainties, particularly in the international market and the China partnership. These negatives outweigh the positives, leading to a negative sentiment prediction for the stock price over the next two weeks.
The earnings call presents a mixed picture. While there is positive guidance with expected revenue growth and international expansion, challenges such as flat Q3 guidance, increased material costs, and declining authorization rates temper optimism. The Q&A session highlights management's efforts to address advertising and reimbursement issues, but uncertainties remain. The lack of clear guidance on pipeline adds and workforce impacts further adds to the neutral sentiment. Given the absence of market cap data, the overall reaction is likely neutral, with no strong catalysts for significant stock movement in either direction.
The earnings call presents mixed signals: strong revenue growth and improved gross margins are offset by challenges in Medicare Advantage authorizations and increased operating expenses. Positive factors like international growth and advertising efficiency are countered by uncertainties in pipeline conversion and lack of shareholder return plans. Management's vague responses in the Q&A add to the uncertainty. Despite strong guidance, the absence of a shareholder return plan and ongoing operational challenges suggest a neutral stock price movement in the short term.
The earnings call shows strong financial performance with a 162% revenue increase and improved gross margins. Despite higher expenses, the company achieved operating cash flow breakeven and provided optimistic guidance for 2025. The Q&A section highlights effective advertising adjustments and sustainable improvements. Although there are concerns about pipeline authorization rates and some unclear management responses, the overall sentiment remains positive, especially with the expansion into international markets and a significant increase in Medicare revenue contribution.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
